Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: David S. who wrote (3678)	1/27/1998
From: JOHN W.	Read Replies (1) of 6136

Elise Wang (1/26/98): "FAVORABBLE CROSS-RESISTANCE PROFILE AS DEMONSTRATED IN CLINICAL DATA: Abstract 510: Virologic response to a Ritonavir/Saquinavir containing regimen in patients who have previously failed Nelfinavir.. Time/Data: Slide Session 65 (Antiretroviral Chemotherapy II), 10:30-12:30pm, Wednesday, Febuary 8. Key Author: P. Tebas, Wsahington University, St. Louis, MO. This abstract presents data on a group of 27 patients who failed Viracept after achieving viral load suppression below levels of detection for at least 52 weeks. 100% of patients (19/19) who were originally protease inhibitor naive responded to the combination of Norvir/Invirase. 43% of patients (3/7) who were highly pre-treated and then failed Viracept still responded to this combination therapy. These results demonstrated that most patients who failed on Viracept responded to a switch to a combination regimen with Norvir/Invirase. This study is supported by a similiar conclusion described in another study presented in Abstract 427. These clinical data support our premise that Viracept represents the optimal first line therapy among protease inhibitors given its ability to generate less cross resistance."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next